These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30294955)

  • 1. Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    de Vries JK; Levin A; Loud F; Adler A; Mayer G; Pena MJ
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):24-29. PubMed ID: 30294955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative systems biology approach for precision medicine in diabetic kidney disease.
    Mulder S; Hamidi H; Kretzler M; Ju W
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl 3):6-13. PubMed ID: 30294956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
    Heerspink HJL; List J; Perkovic V
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):14-18. PubMed ID: 30294954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Mol PGM; Thompson A; Heerspink HJL; Leufkens HGM
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):19-23. PubMed ID: 30294953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating diabetic complications; from large randomized clinical trials to precision medicine.
    Heerspink HJL; de Zeeuw D
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):3-5. PubMed ID: 30294952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
    McGrath K; Edi R
    Am Fam Physician; 2019 Jun; 99(12):751-759. PubMed ID: 31194487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Am J Kidney Dis; 2014 Oct; 64(4):510-33. PubMed ID: 25257325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidiabetics in chronic kidney disease: new questions to new and classical drugs.
    Serra-Tarragón J
    Nefrologia; 2012; 32(6):835; author reply 835-7. PubMed ID: 23169369
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
    Górriz JL; Cos Claramunt FX; Duque N; Matali A
    Prim Care Diabetes; 2019 Dec; 13(6):485-494. PubMed ID: 31400992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned.
    Neumiller JJ; Alicic RZ; Tuttle KR
    Adv Chronic Kidney Dis; 2021 Jul; 28(4):318-327. PubMed ID: 34922688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes.
    Martínez-Castelao A; Górriz JL; Sola E; Morillas C; Jover A; Coronel F; Navarro-González J; De Álvaro F
    Nefrologia; 2012 Jul; 32(4):419-26. PubMed ID: 22806275
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel therapies for diabetic kidney disease.
    Alicic RZ; Tuttle KR
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):121-33. PubMed ID: 24602462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies between the summary of characteristics and the recommended use of metformin in the treatment of type 2 diabetes mellitus patients.
    del Pozo-Fernández C; Pardo-Ruiz C; Sánchez-Botella C; López-Menchero R
    Nefrologia; 2012; 32(6):837-8; author reply 388-9. PubMed ID: 23169370
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Scheen AJ
    Expert Opin Drug Saf; 2020 Mar; 19(3):243-256. PubMed ID: 32083962
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".
    Pugliese G; Penno G; Natali A; Barutta F; Di Paolo S; Reboldi G; Gesualdo L; De Nicola L;
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1127-1150. PubMed ID: 31586514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
    Helou N; Dwyer A; Shaha M; Zanchi A
    JBI Database System Rev Implement Rep; 2016 Jul; 14(7):169-207. PubMed ID: 27532796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision medicine: The future in diabetes care?
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
    Meyer RJ
    Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.
    Lambers Heerspink HJ; Oberbauer R; Perco P; Heinzel A; Heinze G; Mayer G; Mayer B
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv105-112. PubMed ID: 26209732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.